RealFeedApp Company targets commercial revenues in 2028
BioCardia has finished clinical consultations with Japan's PMDA for its CardiAMP cell therapy system, which targets ischemic heart failure. The company plans to treat the first patients and generate commercial revenue in 2028.
- Field
- medicine and diagnostics
- What they did
- BioCardia has finished regulatory consultations in Japan for its cell therapy system CardiAMP, which is designed to treat ischemic heart failure.
- Why it matters
- The company aims to start treating the first patients in Japan and generate commercial revenue by 2028.
#cardiamp#cell therapy#pmda#biocardia#clinical trial
